Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in affective disorders.

Alessandro Serretti1, Roberta Lilli, Enrico Smeraldi

  • 1Department of Psychiatry, Instituto Scientifico H San Raffaele, Vita-Salute University, Fondazione Centro San Raffaele del Monte Tabor, Via Stamira D'Ancona 20, 20127, Milan, Italy. serretti.alessandro@hsr.it

European Journal of Pharmacology
|March 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2021
Same author

Possible Modulatory Role of ARC Gene Variants in Mood Disorders.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2021
Same author

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2021
Same author

Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression.

Current medicinal chemistry·2021
Same author

Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression.

Journal of affective disorders·2020
Same author

Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2020

Pharmacogenetics can significantly improve affective disorder treatments by identifying genetic profiles for drug efficacy and side effects. Preliminary studies suggest specific genes influence treatment outcomes for selective serotonin reuptake inhibitors and lithium.

Area of Science:

  • Psychiatry
  • Pharmacogenetics
  • Neuroscience

Background:

  • Affective disorders pharmacotherapy requires treatments that can take weeks to months to become effective.
  • Identifying genetic factors influencing drug response can optimize treatment strategies.
  • Pharmacogenetics offers a promising approach to personalize treatment for mood disorders.

Purpose of the Study:

  • To review the role of pharmacogenetics in affective disorder pharmacotherapy.
  • To identify potential genetic liability genes for drug side effects and efficacy.
  • To summarize current findings on genetic influences on antidepressant and mood stabilizer treatments.

Main Methods:

  • Literature review of studies investigating genetic polymorphisms and pharmacotherapy outcomes in affective disorders.

Related Experiment Videos

  • Analysis of associations between specific genes (e.g., SERTPR, TPH, 5-HT2a receptor) and treatment response.
  • Evaluation of preliminary data and replicated findings.

    • Main Results:

    • Selective serotonin reuptake inhibitor (SSRI) efficacy and onset are associated with SERTPR promoter polymorphism in multiple studies.
    • Pilot studies suggest associations between SSRI response and variants in tryptophan hydroxylase (TPH), 5-HT2a receptor, and G-protein beta3.
    • Lithium's long-term efficacy has preliminary associations with SERTPR, TPH, and inositol polyphosphate 1-phosphatase variants, though these require replication.

    Conclusions:

    • Both acute and long-term treatments for affective disorders are influenced by genetic factors.
    • Preliminary data have identified candidate genes that may serve as liability markers for treatment response.
    • Pharmacogenetics holds substantial potential for improving the personalized pharmacotherapy of affective disorders.